{"id":"cerulenin","rwe":[{"pmid":"41764192","year":"2026","title":"Targeting fatty acid synthase suppresses tumor development in NF2/CDKN2A-deficient pleural mesothelioma.","finding":"","journal":"Cell death & disease","studyType":"Clinical Study"},{"pmid":"41648176","year":"2026","title":"Spindle biochemistry responds to compressive force from the nuclear envelope to tune spindle dynamics during closed mitosis.","finding":"","journal":"bioRxiv : the preprint server for biology","studyType":"Clinical Study"},{"pmid":"41324644","year":"2025","title":"Modulating stilbenes in peanut cells: a novel approach with metabolic modulators.","finding":"","journal":"Plant cell reports","studyType":"Clinical Study"},{"pmid":"41242917","year":"2026","title":"Corrigendum to \"Synergistic targeting of FASN and HMGCS1 by cerulenin enhances tumor cell ferroptosis sensitivity through rewiring lipid metabolism and blocking GPX4 biosynthesis\" [Cancer Lett. (2025) 633 217992].","finding":"","journal":"Cancer letters","studyType":"Clinical Study"},{"pmid":"41196069","year":"2025","title":"Fatty acid synthase may facilitate the trafficking of bovine alpha herpesvirus 1 out of the Golgi apparatus, potentially promoting viral infection.","finding":"","journal":"Microbiology spectrum","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Coagulation factor XIII A chain","category":"target"},{"label":"F13A1","category":"gene"},{"label":"FASN","category":"gene"},{"label":"Active","category":"status"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antifungal Agents","category":"pharmacology"},{"label":"Antimetabolites","category":"pharmacology"},{"label":"Fatty Acid Synthesis Inhibitors","category":"pharmacology"},{"label":"Hypolipidemic Agents","category":"pharmacology"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"helicocerin","offLabel":[],"synonyms":["cerulenin","helicocerin","(+)-Cerulenin"],"timeline":[],"approvals":[],"brandName":"Helicocerin","ecosystem":[],"mechanism":{"target":"Coagulation factor XIII A chain, Fatty acid synthase, Pol polyprotein","targets":[{"gene":"F13A1","source":"DrugCentral","target":"Coagulation factor XIII A chain","protein":"Coagulation factor XIII A chain"},{"gene":"FASN","source":"DrugCentral","target":"Fatty acid synthase","protein":"Fatty acid synthase"}],"modality":"Small Molecule","explanation":"Think of blood clotting like a glue that holds a cut together. Coagulation factor XIII A chain is a key part of this glue, helping to strengthen the clot and keep it from falling apart. Helicocerin blocks this glue from working properly, which can help prevent excessive blood clotting.","oneSentence":"Helicocerin works by inhibiting the activity of coagulation factor XIII A chain, a protein involved in blood clotting.","technicalDetail":"Helicocerin specifically inhibits the transglutaminase activity of coagulation factor XIII A chain, preventing the formation of covalent bonds between fibrin molecules and stabilizing the blood clot."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/578","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=cerulenin","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:31:46.291673","biosimilars":[],"competitors":[{"drugName":"lansoprazole","drugSlug":"lansoprazole","fdaApproval":"1995-05-10","patentExpiry":"Apr 21, 2036","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"omeprazole","drugSlug":"omeprazole","fdaApproval":"1989-09-14","patentExpiry":"Dec 8, 2036","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"orlistat","drugSlug":"orlistat","fdaApproval":"1999-04-23","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"pantoprazole","drugSlug":"pantoprazole","fdaApproval":"2000-02-02","patentExpiry":"Jun 7, 2026","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"rabeprazole","drugSlug":"rabeprazole","fdaApproval":"1999-08-19","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"cerulenin","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"lansoprazole","brandName":"lansoprazole","genericName":"lansoprazole","approvalYear":"1995","relationship":"same-target"},{"drugId":"omeprazole","brandName":"omeprazole","genericName":"omeprazole","approvalYear":"1989","relationship":"same-target"},{"drugId":"orlistat","brandName":"orlistat","genericName":"orlistat","approvalYear":"1999","relationship":"same-target"},{"drugId":"pantoprazole","brandName":"pantoprazole","genericName":"pantoprazole","approvalYear":"2000","relationship":"same-target"},{"drugId":"rabeprazole","brandName":"rabeprazole","genericName":"rabeprazole","approvalYear":"1999","relationship":"same-target"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"MF286Y830Q","CHEBI":"CHEBI:171741","UMLSCUI":"C0007839","ChEMBL_ID":"CHEMBL45627","DRUGBANK_ID":"DB01034","PDB_CHEM_ID":" 1X9","PUBCHEM_CID":"5282054","MESH_DESCRIPTOR_UI":"D002569"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":772,"therapeuticAreas":["Hematology"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Feb 28","pmid":"41764192","title":"Targeting fatty acid synthase suppresses tumor development in NF2/CDKN2A-deficient pleural mesothelioma.","journal":"Cell death & disease"},{"date":"2026 Jan 15","pmid":"41648176","title":"Spindle biochemistry responds to compressive force from the nuclear envelope to tune spindle dynamics during closed mitosis.","journal":"bioRxiv : the preprint server for biology"},{"date":"2025 Dec 1","pmid":"41324644","title":"Modulating stilbenes in peanut cells: a novel approach with metabolic modulators.","journal":"Plant cell reports"},{"date":"2026 Jan 1","pmid":"41242917","title":"Corrigendum to \"Synergistic targeting of FASN and HMGCS1 by cerulenin enhances tumor cell ferroptosis sensitivity through rewiring lipid metabolism and blocking GPX4 biosynthesis\" [Cancer Lett. (2025) 633 217992].","journal":"Cancer letters"},{"date":"2025 Dec 2","pmid":"41196069","title":"Fatty acid synthase may facilitate the trafficking of bovine alpha herpesvirus 1 out of the Golgi apparatus, potentially promoting viral infection.","journal":"Microbiology spectrum"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Helicocerin, also known as cerulenin, is a small molecule modality targeting coagulation factor XIII A chain. Its exact drug class is unknown, and it has not been approved by the FDA for any indications. As a result, its commercial status, half-life, bioavailability, and generic manufacturers are also unknown. Further research is needed to fully understand its potential as a therapeutic agent. Its safety profile and efficacy have not been extensively studied.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}